Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: GT who wrote (10746)	11/13/1998 8:39:00 AM
From: JSB	Respond to of 119973

How low does ENMD go from here? After Mark finished him off, it should be a screaming short. Regards, Jeff

To: GT who wrote (10746)	11/13/1998 8:43:00 AM
From: Gregg Sterner	Read Replies (5) \| Respond to of 119973

CTII looks like a it ready take it place. LINCOLN, R.I., Nov 9 (Reuters) - CytoTherapeutics, Inc., a developer of gene and cell-based drugs, said Monday the U.S. Patent Office has allowed its patent application for the use of its encapsulated cell technology to treat eye diseases. The company said encapsulated-cell technology is designed to treat serious ailments by delivering therapeutic substances directly to body part where they are needed. CytoTherapeutics stock was up 9/32 at 2-1/8 in midday trading on the the Nasdaq Stock Market on a volume of 1.4 million shares -- an estimated 10 times its average trading volume. The company said the patent provides it with broad coverage and a "clear commercial pathway" to develop products to treat a number of serious eye disorders that are poorly treated or untreatable. The company said the allowed patent covers methods for delivering one or more biologically active molecules to the eye through encapsulated cell implants placed intraocularly, circumventing the blood-retina barrier, or periocularly. The company said its encapsulated cell implant technology potentially avoids problems such as toxicity and tolerance associated with other forms of drug delivery because the agent is surgically placed in the body to deliver a desired therapeutic substance directly where it is needed. Copyright 1998, Reuters News Service Companies or Securities discussed in this article: Symbol Name NASDAQ:CTII Cytotherapeutics Inc